Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
21.36
+0.58 (2.79%)
At close: Feb 11, 2026, 4:00 PM EST
21.36
0.00 (0.00%)
After-hours: Feb 11, 2026, 7:00 PM EST
Arcus Biosciences Stock Forecast
Stock Price Forecast
The 9 analysts that cover Arcus Biosciences stock have a consensus rating of "Buy" and an average price target of $28.89, which forecasts a 35.25% increase in the stock price over the next year. The lowest target is $14 and the highest is $56.
Price Target: $28.89 (+35.25%)
Analyst Consensus: Buy
* Price targets were last updated on Jan 13, 2026.
Analyst Ratings
The average analyst rating for Arcus Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 3 | 3 | 3 | 4 | 4 |
| Buy | 5 | 3 | 3 | 3 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $16 → $28 | Hold → Strong Buy | Upgrades | $16 → $28 | +31.09% | Jan 13, 2026 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $23 → $20 | Buy → Hold | Downgrades | $23 → $20 | -6.37% | Jan 8, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $28 → $32 | Strong Buy | Maintains | $28 → $32 | +49.81% | Dec 12, 2025 |
| B of A Securities | B of A Securities | Hold Maintains $17 → $26 | Hold | Maintains | $17 → $26 | +21.72% | Nov 28, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $14 → $16 | Hold | Maintains | $14 → $16 | -25.09% | Oct 30, 2025 |
Financial Forecast
Revenue This Year
251.47M
from 258.00M
Decreased by -2.53%
Revenue Next Year
122.68M
from 251.47M
Decreased by -51.21%
EPS This Year
-3.50
from -3.14
EPS Next Year
-4.01
from -3.50
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 352.7M | 253.0M | ||||
| Avg | 251.5M | 122.7M | ||||
| Low | 224.4M | 6.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 36.7% | 0.6% | ||||
| Avg | -2.5% | -51.2% | ||||
| Low | -13.0% | -97.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.90 | -3.33 | ||||
| Avg | -3.50 | -4.01 | ||||
| Low | -3.76 | -4.75 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.